| (19) |
 |
|
(11) |
EP 0 161 901 A3 |
| (12) |
EUROPEAN PATENT APPLICATION |
| (88) |
Date of publication A3: |
|
04.03.1987 Bulletin 1987/10 |
| (43) |
Date of publication A2: |
|
21.11.1985 Bulletin 1985/47 |
| (22) |
Date of filing: 07.05.1985 |
|
|
| (84) |
Designated Contracting States: |
|
BE CH DE FR GB IT LI NL SE |
| (30) |
Priority: |
18.05.1984 US 611669 11.02.1985 US 700374
|
| (71) |
Applicants: |
|
- NEW ENGLAND MEDICAL CENTER HOSPITALS, INC.
()
- THE TRUSTEES OF TUFTS COLLEGE
()
- WELLESLEY COLLEGE
()
- MASSACHUSETTS INSTITUTE OF TECHNOLOGY
()
|
|
| (72) |
Inventors: |
|
- Auron, Philip E.
()
- Webb, Andrew C.
()
- Gehrke, Lee
()
- Dinarello, Charles A.
()
- Rosenwasser, Lanny J.
()
- Rich, Alexander
()
- Wolff, Sheldon M.
()
|
|
| |
|
| (54) |
Human il-1 cDNA sequences encoding biologically-active human il-1 proteins |
(57) Nucleic acids comprise a nucleotide sequence encoding human interleukin-1 (IL-1),
and fragments thereof, and the polypeptides and peptides obtained. Truncated human
IL-1 cDNA sequences encode biologically-active novel human IL-1 proteins. cDNA synthesised
by reverse transcription of poly-(A)RNA isolated from adherent human monocytes stimulated
with bacterial endotoxin, is cloned. Truncated human IL-1 cDNA sequences can be obtained
by genetic engineering procedures using cloned human IL-1 cDNA as a starting material.
Human IL-1 and human IL-1 proteins obtained via cloned truncated human IL-1 cDNA sequences
can induce the production of IL-2 by activated T-cells; they also act on B-cells and
NK-cells.